Importantly, mono-allelic deletion of PTEN has been reported in up to 68% of prostate cancer surgical specimens and PTEN immunohistochemistry (IHC) and/or fluorescent in situ hybridization analysis has revealed PTEN loss may occur in as many as 60% of advanced/CRPC cases [92]. Here, PTEN is linked to prostate carcinoma.